Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma

• Published in: Nature communications Vol. 12; no. 1; p. 5262
• Main Authors: Sun, Guangxi, Chen, Junru, Liang, Jiayu, Yin, Xiaoxue, Zhang, Mengni, Yao, Jin, He, Ning, Armstrong, Cameron M., Zheng, Linmao, Zhang, Xingming, Zhu, Sha, Sun, Xiaomeng, Yang, Xiaoxia, Zhao, Wanbin, Liao, Banghua, Pan, Xiuyi, Nie, Ling, Yang, Ling, Chen, Yuntian, Zhao, Jinge, Zhang, Haoran, Dai, Jindong, Shen, Yali, Liu, Jiyan, Huang, Rui, Liu, Jiandong, Wang, Zhipeng, Ni, Yuchao, Wei, Qiang, Li, Xiang, Zhou, Qiao, Huang, Haojie, Liu, Zhenhua, Shen, Pengfei, Chen, Ni, Zeng, Hao
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 06.09.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 38/23; 38/39; 49/91; 631/208/199; 631/208/69; 631/67/589/1588/1351; 631/67/69; Angiogenesis; Cancer; Copy number; Gene sequencing; Genomics; Humanities and Social Sciences; Kidney cancer; Kidneys; Lymphocytes T; Metastases; Molecular clusters; multidisciplinary; PD-L1 protein; Precision medicine; Renal cell carcinoma; Science; Science (multidisciplinary); Stroma; Transcriptomics; Translocation; Tumors
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-021-25618-z

TFE3 -translocation renal cell carcinoma ( TFE3 -tRCC) is a rare and heterogeneous subtype of kidney cancer with no standard treatment for advanced disease. We describe comprehensive molecular characteristics of 63 untreated primary TFE3 -tRCCs based on whole-exome and RNA sequencing. TFE3 -tRCC is highly heterogeneous, both clinicopathologically and genotypically. ASPSCR1-TFE3 fusion and several somatic copy number alterations, including the loss of 22q, are associated with aggressive features and poor outcomes. Apart from tumors with MED15-TFE3 fusion, most TFE3 -tRCCs exhibit low PD-L1 expression and low T-cell infiltration. Unsupervised transcriptomic analysis reveals five molecular clusters with distinct angiogenesis, stroma, proliferation and KRAS down signatures, which show association with fusion patterns and prognosis. In line with the aggressive nature, the high angiogenesis/stroma/proliferation cluster exclusively consists of tumors with ASPSCR1-TFE3 fusion. Here, we describe the genomic and transcriptomic features of TFE3 -tRCC and provide insights into precision medicine for this disease. TFE3-translocation renal cell carcinoma (TFE3-tRCC) is a rare subtype of kidney cancer with no standard treatment options for the advanced disease. Here, the authors perform genomic and transcriptomic profiling of 63 untreated primary TFE3-tRCC tumours and reveal potential therapeutic targets.